Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pharmacology and clinical experience with risperidone.

R C Love1, M W Nelson

  • 1University of Maryland, Baltimore, 100 Penn Street, Room 505, Baltimore, MD 21201, USA. love@pharmacy.ab.umd.edu

Expert Opinion on Pharmacotherapy
|March 16, 2001
PubMed
Summary

Risperidone, a second-generation antipsychotic, effectively treats schizophrenia symptoms with fewer side effects than older drugs. It offers a cost-effective, new standard of care for psychotic disorders.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ziprasidone and the QTc interval: pharmacokinetic and pharmacodynamic considerations.

Psychopharmacology bulletin·2002
Same author

Spatially correlated fluorescence/AFM of individual nanosized particles and biomolecules.

Analytical chemistry·2001
Same author

Comparison of discharge rates and drug costs for patients with schizophrenia treated with risperidone or olanzapine.

Psychiatric services (Washington, D.C.)·2001
Same author

A dose-outcome analysis of risperidone.

The Journal of clinical psychiatry·1999
Same author

Rehospitalization rates of patients recently discharged on a regimen of risperidone or clozapine.

The American journal of psychiatry·1999
Same author

Rehospitalization rates for depot antipsychotics and pharmacoeconomic implications: comparison with risperidone.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·1999

Area of Science:

  • Psychopharmacology
  • Neuroscience

Background:

  • Risperidone is a second-generation antipsychotic (SGA) used for schizophrenia and psychotic disorders.
  • It acts as a potent antagonist of serotonin-2 (5-HT2) and dopamine-2 (D2) receptors.

Purpose of the Study:

  • To evaluate the efficacy and side effect profile of risperidone.
  • To assess its cost-effectiveness in treating psychotic disorders.

Main Methods:

  • Pharmacological antagonism of 5-HT2 and D2 receptors.
  • Comparative analysis against conventional antipsychotics and other SGAs.
  • Pharmacoeconomic evaluations.

Main Results:

  • Superior efficacy against positive and negative symptoms of schizophrenia.

Related Experiment Videos

  • Decreased occurrence of extrapyramidal side effects (EPS) compared to conventional antipsychotics.
  • Less weight gain than other SGAs, but potential for dose-related EPS and increased prolactin levels.

    • Conclusions:

    • Risperidone represents a cost-effective treatment option.
    • It has established a new standard of care for psychotic disorders as an early front-line therapy.